Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin

Circulation

Volumn 110, Issue 4, 2004, Pages 392-398

  Montalescot, G ^a   Collet, J P ^a   Tanguy, M L ^a   Ankri, A ^a   Payot, L ^a   Dumaine, R ^a   Choussat, R ^a   Beygui, F ^a   Gallois, V ^a   Thomas, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Acute coronary syndrome; Enoxaparin; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BIOLOGICAL MARKERS; COHORT STUDIES; COMBINED MODALITY THERAPY; CREATINE KINASE; CREATINE KINASE, MB FORM; DRUG THERAPY, COMBINATION; ENOXAPARIN; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEMORRHAGE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME; TROPONIN I;

EID: 3342901810     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136830.65073.C7     Document Type: Article

References (36)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S.
2. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
3. Whitfield LR, Levy G. Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences. Clin Pharmacol Ther. 1980;28:509-516.
4. Brandt JT, Triplett DA. Laboratory monitoring of heparin: effects of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol. 1981;76:530-537.
5. Chiu HM, Hirsh J, Yung WL, et al. Relationship between the anticoagulant effect and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
6. van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated thromboplastin time and heparin assays based on ex vivo heparin samples. Thromb Haemost. 1990;63:16-23.
7. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-1900.
8. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28-66.
9. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107:2884-2888.
10. Gilchrist IC, Berkowitz SD, Thompson TD, et al. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Am Heart J. 2002;144:73-80.
11. Hyers TM, Hull RD, Morris TA, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S-193S.
12. Martin JL, Fry ETA, Sanderink GCM, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention (PCI): the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Cathet Cardiovasc Interv. 2004;61:163-170.
13. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention following subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris. Circulation. 2001;103:658-663.
14. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cordiol. 2003;41:8-14.
15. Sabatine MS, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;41:895-955.
16. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003;146:628-633.
17. Kereiakes DJ, Montalescot G, Amman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J. 2002;144:615-624.
18. The SYNERGY steering committee. The SYNERGY trial: study design and rationale. Am Heart J. 2002;143:952-960.
19. Enoxaparin Sodium Investigator Brochure. 12th ed. Bridgewater, NJ: Aventis Pharma; January 31, 2003.
20. The Thrombolysis in Myocardial Infarction (TIMI) 11A Investigators. Dose-ranging trial of enoxaparin for unstable angina patients: results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474-1482.
21. Bijsterveld NR, Moons AH, Meijers JCM, et al. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol. 2003;42:424-427.
22. Moscucci M, Fox KAA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events. Eur Heart J. 2003;24:1815-1823.
23. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81-82.
24. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
25. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
26. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparins to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320:352-357.
27. Klein W, Buchwald A, Hills WS, et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol. 1997;80:30E-34E.
28. FRISC-II Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC-II prospective randomized multicentre trial. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease. Lancet. 1999;354:701-707.
29. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischaemia. J Am Coll Cardiol. 1995;26:313-318.
30. Anonymous. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXiparine in Ischaemic Syndrome (FRAX.I.S). Eur Heart J 1999;20:1553-1562.
31. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447-452.
32. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
33. Montalescot G, Bal-dit-Sollier C, Chibedi D, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol 2003;91:925-930.
34. Montalescot G, Phillipe F, Ankri A, et al. Early increase of von Willebrand actor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation. 1998;98:294-299.
35. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand release in unstable angina. J Am Coll Cardiol. 2000;36:110-114.
36. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.